Dietary sinapic acid also improved gut microbiota imbalance and IBD symptoms, suggesting its potential as a nutraceutical and pharmaceutical agent for IBD treatment by targeting TAK1 and inhibiting subsequent NF-κB and ATF-2 signaling. The gene discussed is ATF2; the disease is inflammatory bowel disease.